HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Martin L. Dalton Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Graham, B. L. Articles by Lambuth, B. Search for Related Content PubMed PubMed Citation Articles by Graham, B. L., Jr. Articles by Lambuth, B.

Ann Thorac Surg 1988;45:687-692
© 1988 The Society of Thoracic Surgeons

---

Articles

Surgery in Small Cell Lung Cancer

Division of Medical Oncology and Thoracic Surgery, University of Mississippi Medical Center, and the Division of Medical Oncology, VA Medical Center, University of Mississippi Medical Center, Jackson, MS

^* Address reprint requests to Dr. Khansur, VA Medical Center (151), 1500 E. Woodrow Wilson Dr, Jackson, MS 39216

Surgery in small cell lung cancer (SCLC) was abandoned in the late 1960s but is currently being cautiously reassessed, after the Armed Forces Asymptomatic Pulmonary Nodule Study demonstrated an unexpectedly prolonged 5-year survival (36%) with surgery. Subsequent prospective studies have reported five-year survival following resection in 22 to 83% of patients with Stage I disease and in 0 to 50% of patients with Stages II and III disease. Ten percent of patients with SCLC may be amenable to this approach. Additional patients may become candidates for resection following intensive combination chemotherapy. The optimal postoperative management remains unsettled. Combination chemotherapy and prophylactic cranial irradiation is recommended following complete resection. Postoperative thoracic irradiation may benefit patients with pathologically involved mediastinal nodes. Correlation of clinical response with our new understanding of the molecular biology of SCLC may further improve our approach to this disease.

This article has been cited by other articles:

				G. M. Salzer, L. C. Muller, H. Huber, H. Denz, R. Gasser, H. Frommhold, and I. Ebner Operation for N2 small cell lung carcinoma Ann. Thorac. Surg., May 1, 1990; 49(5): 759 - 762. [Abstract] [PDF]

				D. W. McFadden, M. Rudnicki, and M. A. Talamini Primary small cell carcinoma of the esophagus Ann. Thorac. Surg., March 1, 1989; 47(3): 477 - 480. [Abstract] [PDF]